Key statistics
On Thursday, Ryvu Therapeutics SA (9Y4:DUS) closed at 11.52, 8.07% above its 52-week low of 10.66, set on May 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.06 |
---|---|
High | 12.06 |
Low | 11.52 |
Bid | 11.52 |
Offer | 12.88 |
Previous close | 11.80 |
Average volume | 0.00 |
---|---|
Shares outstanding | 23.12m |
Free float | 14.99m |
P/E (TTM) | -- |
Market cap | 1.23bn PLN |
EPS (TTM) | -4.15 PLN |
Data delayed at least 15 minutes, as of Oct 10 2024 18:31 BST.
More ▼
Press releases
- Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium
- Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit
- Ryvu Therapeutics Announces Dosing of the First Patient in the REMARK Phase II Study of RVU120 for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
- Ryvu Therapeutics Reports 2024 Half-Year Financial Results and Provides Corporate Update